AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial
AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive.